CLINICAL AND PHARMACOLOGICAL EVALUATION OF BUPRENORPHINE AND NALOXONE COMBINATIONS: WHY THE 4:1 RATIO FOR TREATMENT?
Shranjeno v:
MENDELSON, J., JONES, R.T., CLINICAL AND PHARMACOLOGICAL EVALUATION OF BUPRENORPHINE AND NALOXONE COMBINATIONS: WHY THE 4:1 RATIO FOR TREATMENT?. DRUG AND ALCOHOL DEPENDENCE, Vol. 70, no. 2 SUPL. (2003), p. S29-S37.
Ref.
121190
Lokacija:
SIIS R.854 Archivo
Palabras clave:
Antagonistas, Buprenorfina, Características, Dosis, Drogodependencias, Fármacos, Heroína, Programas de desintoxicación, Programas de mantenimiento
Antagonistas, Buprenorfina, Características, Dosis, Drogodependencias, Fármacos, Heroína, Programas de desintoxicación, Programas de mantenimiento
Podobne knjige/članki: CLINICAL AND PHARMACOLOGICAL EVALUATION OF BUPRENORPHINE AND NALOXONE COMBINATIONS: WHY THE 4:1 RATIO FOR TREATMENT?
- PHARMACOKINETICS OF THE COMBINATION TABLET OF BUPRENORPHINE AND NALOXONE
- THE CLINICAL PHARMACOLOGY OF BUPRENORPHINE: EXTRAPOLATING FROM THE LABORATORY TO THE CLINIC
- BUPRENORPHINE: HOW TO USE IT RIGHT
- SAFETY AND HEALTH POLICY CONSIDERATIONS RELATED TO THE USE OF BUPRENORPHINE/NALOXONE AS AN OFFICE-BASED TREATMENT FOR OPIATE DEPENDENCE
- BUPRENORPHINE TREATMENT OF OPIUM-DEPENDENT OUTPATIENTS SEEKING TREATMENT IN IRAN
- NATIONAL CLINIC GUIDELINES AND PROCEDURES FOR THE USE OF BUPRENORPHINE IN THE TREATMENT OF HEROIN DEPENDENCE